Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Degarelix vs GnRH Agonist CV Safety in Prostate Cancer
NCT04182594Phase 2Unknown
- Sponsor
- Rabin Medical Center
- Start
- Jan 2020
- Primary completion
- Jan 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of degarelix in prostate cancer (PCa) (2 arms), sponsored by Rabin Medical Center. Primary endpoint: Time to first cardiovascular event at 1 year. Status: unknown.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04182594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04182594.